Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
108 participants
INTERVENTIONAL
2010-12-31
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Serotonin, Impulsivity, and Cocaine Dependence Treatment
NCT00297505
Brain Function and Structure in Cocaine Dependence
NCT02080832
Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8
NCT00218036
Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2
NCT00000310
Alterations in Serotonergic Functions in Cocaine Addicts - 1
NCT00000312
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Citalopram low dose
Citalopram 20 mg
Citalopram
20 mg once per day for 9 weeks
Citalopram high dose
Citalopram 40 mg
Citalopram
40 mg per day for 9 weeks
Placebo
Placebo
Placebo
0 mg per day for 9 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Citalopram
20 mg once per day for 9 weeks
Citalopram
40 mg per day for 9 weeks
Placebo
0 mg per day for 9 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* meet Diagnostic and Statistical Manual 4 (DSM-IV) criteria for current cocaine dependence
* be in acceptable health on the basis of interview, medical history and physical exam
* able to provide the names of at least 2 persons who can generally locate their whereabouts.
Exclusion Criteria
* have a psychiatric disorder or neurological disease or disorder requiring ongoing treatment and/or making study participation unsafe
* medical conditions contraindicating citalopram pharmacotherapy
* taking medications known to have significant drug interactions with the study medication
* pregnant or nursing for female patients
* having plans to leave the immediate geographical area within 3 months
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Joy Schmitz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joy Schmitz
Professor , Behavioral Sciences
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joy M Schmitz, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Texas at Houston
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UT-Houston Behavioral and Biomedical Sciences Building
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.